🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementFAERS pharmacovigilance data for semaglutide — anyone have experience? Page 6

FAERS pharmacovigilance data for semaglutide — anyone have experience?

bri_stats Thu, Mar 21, 2024 at 2:29 PM 36 replies 2,800 viewsPage 6 of 8
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Apr 13, 2024 at 10:21 AM#26
Dr.ObesityLA said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

Adding a me-too, because a thread of one person's experience is not much use.

Last edited: Apr 13, 2024 at 2:21 PM
13 11NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 10 others
Reply Quote Save Share Report
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Apr 15, 2024 at 2:49 PM#27
Dr.ObesityLA said:
The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

There is a second half to this that has not been said yet. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

14 12stefan_berlin, Dr.EM_Chicago, pete_RVA and 11 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Apr 17, 2024 at 7:16 PM#28

The figures, for anyone assembling their own picture. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

15 13patPC_UT, Dr.DermMIA, fiona_VT and 12 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Apr 19, 2024 at 11:42 PM#29

A narrower follow-up, since the general answer is now clear:

What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?

Last edited: Apr 20, 2024 at 4:42 AM
16 14Dr.PeteFamMed, claudia_zurich, nancy_portland and 13 others
Reply Quote Save Share Report
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Apr 22, 2024 at 4:06 AM#30

Closing the loop on my own question.

Following this thread I went back and re-read the extension data properly. The point about trough rather than peak explains the pattern I was seeing on day six, which I had been blaming on the vial.

38 11julia.endo, JessicaM_2024, TomFromTexas and 35 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register